Interpace Diagnostics

Interpace Diagnostics is a healthcare commercialization company providing go-to-market strategy and execution to established and emerging pharmaceutical, biotechnology, diagnostics and healthcare companies in the United States. The company operates a molecular diagnostics company that helps physicians better manage patients at risk for certain types of gastrointestinal cancers through its proprietary PathFinderTG platform. Its PathfinderTG platform uses advanced clinical algorithms to accurately stratify patients according to risk of cancer by assessing panels of DNA abnormalities in patients who have lesions (i.e., cysts or solid masses) with potential for cancer.
Type
Public
HQ
Parsippany Troy Hills, US
Founded
1987
Size (employees)
65 (est)
Interpace Diagnostics was founded in 1987 and is headquartered in Parsippany-Troy Hills, US

Interpace Diagnostics Office Locations

Interpace Diagnostics has an office in Parsippany-Troy Hills
Parsippany Troy Hills, US (HQ)
300 Interpace Pkwy

Interpace Diagnostics Data and Metrics

Interpace Diagnostics Financial Metrics

Interpace Diagnostics's revenue was reported to be $3.5 m in Q1, 2017
USD

Revenue (Q1, 2017)

3.5 m

Gross profit (Q1, 2017)

1.7 m

Gross profit margin (Q1, 2017), %

49%

Net income (Q1, 2017)

2.4 m

EBIT (Q1, 2017)

3.7 m

Market capitalization (19-Jul-2017)

7.6 m

Closing share price (19-Jul-2017)

0.9

Cash (31-Mar-2017)

7.1 m
Interpace Diagnostics's current market capitalization is $7.6 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

150.8 m119.9 m9.4 m13.1 m

Revenue growth, %

(20%)(92%)39%

Cost of goods sold

126.4 m101.4 m6.9 m6.6 m

Gross profit

24.4 m18.5 m2.5 m6.4 m

Gross profit Margin, %

16%15%27%49%

Sales and marketing expense

5.5 m

R&D expense

1.6 m

General and administrative expense

10.5 m

Operating expense total

28.7 m32 m42.9 m12.9 m

EBIT

(4.3 m)(13.5 m)(40.4 m)(6.4 m)

EBIT margin, %

(3%)(11%)(428%)(49%)

Interest expense

602 k3.7 m(2.1 m)

Net Income

(4.6 m)(16.1 m)(11.4 m)(8.3 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

31.6 m29.2 m38.3 m36.3 m36.6 m3 m3.6 m3.3 m3.5 m

Cost of goods sold

26.8 m25.5 m30.7 m30.2 m29.4 m1.2 m1.8 m1.8 m1.8 m

Gross profit

4.8 m3.7 m7.6 m6.1 m7.2 m1.9 m1.8 m1.5 m1.7 m

Gross profit Margin, %

15%13%20%17%20%61%49%44%49%

Sales and marketing expense

1.5 m1.3 m1.3 m1.1 m

R&D expense

232 k414 k1 m323 k357 k659 k306 k

General and administrative expense

7.2 m7.3 m6.4 m2.8 m2 m2.9 m1.5 m

Operating expense total

7.4 m7.8 m7.4 m4.7 m3.7 m4.8 m3 m

EBIT

(2.5 m)(4.2 m)(2.9 m)(5.9 m)(4 m)(3.8 m)(2.9 m)(6.5 m)3.7 m

EBIT margin, %

(8%)(14%)(8%)(16%)(11%)(125%)(80%)(196%)107%

Interest expense

(848 k)(884 k)(969 k)(203 k)(858 k)(539 k)(254 k)

Income tax expense

173 k3 k

Net Income

(2.7 m)(4.3 m)(3.9 m)(7 m)(4.9 m)(4.8 m)(2.3 m)(7.5 m)2.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

45.6 m23.1 m8.3 m602 k

Accounts Receivable

2.4 m8.5 m2.8 m2.2 m

Current Assets

62.7 m44.9 m19.2 m4.2 m

PP&E

2.8 m3.2 m1.5 m929 k

Goodwill

2.5 m15.5 m

Total Assets

69.1 m115.9 m67.7 m41.8 m

Accounts Payable

2.4 m4.3 m1.6 m2.3 m

Total Debt

27.2 m8.4 m

Current Liabilities

31.4 m33.6 m23.4 m16.2 m

Total Liabilities

35.2 m

Additional Paid-in Capital

130.2 m134.2 m132.5 m127.7 m

Retained Earnings

(83.8 m)(99.9 m)(111.3 m)(119.6 m)

Total Equity

32.5 m20.1 m13 m6.5 m

Debt to Equity Ratio

1.3 x0.6 x

Debt to Assets Ratio

0.2 x0.1 x

Financial Leverage

2.1 x5.8 x5.2 x6.4 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

35.6 m27 m17 m14.4 m9 m4.3 m3 m1.7 m7.1 m

Accounts Receivable

3.8 m3.4 m13.4 m11.9 m12.3 m2.8 m3 m2.8 m2.3 m

Current Assets

53.2 m42.2 m43.1 m39.3 m32.1 m11.7 m9.6 m6.7 m10.7 m

PP&E

2.8 m2.9 m3.3 m3.1 m2.8 m1.3 m1.2 m1.1 m770 k

Goodwill

2.5 m2.5 m15.5 m15.7 m15.7 m

Total Assets

59.5 m62.2 m112.6 m107.6 m99.3 m56.8 m53.5 m46 m47 m

Accounts Payable

2.1 m2.9 m3 m4.4 m4.5 m1.2 m1.3 m1.4 m2.6 m

Current Liabilities

25.6 m28.7 m34 m34.9 m31.5 m19.7 m19.2 m19.9 m13 m

Additional Paid-in Capital

131.6 m132 m134.6 m129.1 m129.6 m125.8 m125.8 m125.8 m143.3 m

Retained Earnings

(88.1 m)(92.4 m)(103.8 m)(110.7 m)(115.6 m)(116 m)(118.4 m)(125.9 m)(117.2 m)

Total Equity

29.4 m25.4 m16.6 m10.3 m5.9 m8.3 m6 m24.6 m

Financial Leverage

2 x2.4 x6.8 x10.4 x16.9 x6.8 x8.9 x1.9 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(4.6 m)(16.1 m)(11.4 m)(8.3 m)

Depreciation and Amortization

4.5 m

Accounts Receivable

4.8 m

Accounts Payable

143 k

Cash From Operating Activities

(3.5 m)(16.4 m)(19.8 m)(8.9 m)

Purchases of PP&E

(1.8 m)(2.9 m)(353 k)

Cash From Investing Activities

(3.3 m)(25.4 m)26.4 m

Cash From Financing Activities

(314 k)19.2 m(21.4 m)1.2 m

Income Taxes Paid

235 k115 k242 k71 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(2.7 m)(4.3 m)(3.9 m)(7 m)(4.9 m)(4.8 m)(2.3 m)(7.5 m)2.4 m

Accounts Receivable

3.8 m3.4 m13.4 m11.9 m12.3 m2.8 m3 m2.8 m2.3 m

Accounts Payable

2.1 m2.9 m3 m4.4 m4.5 m1.2 m1.3 m1.4 m2.6 m
USDY, 2017

Revenue/Employee

53.4 k

Financial Leverage

1.9 x

Interpace Diagnostics Operating Metrics

Interpace Diagnostics's Facilities was reported to be 2 in FY, 2016. Interpace Diagnostics's Patent Applications was reported to be 16 in FY, 2016
FY, 2016

Facilities

2

Patents (foreign)

3

Products

3

Patents (US)

1

Patent Applications

16

Interpace Diagnostics Market Value History

Interpace Diagnostics Online and Social Media Presence

Interpace Diagnostics Company Life and Culture

You may also be interested in